The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery
1 other identifier
interventional
80
1 country
1
Brief Summary
The aim of this clinical trial is to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative blood loss, thromboembolic complications, and hospitalization duration in patients undergoing knee joint arthroplasty. Also aim to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative thromboembolic complications, and hospitalization duration
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Jul 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 9, 2025
CompletedStudy Start
First participant enrolled
July 15, 2025
CompletedFirst Posted
Study publicly available on registry
July 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 24, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 24, 2027
July 28, 2025
July 1, 2025
1.9 years
July 9, 2025
July 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Perioperative blood loss
Calculated 24 h blood loss in mL, Hidden blood loss in mL, Hemoglobin levels in g/dL, Hematocrit levels as a percentage, Platelets count in cells/µL.
Daily, till post-operative day 5
Secondary Outcomes (4)
Thromboembolic complications
Daily, till post-operative day 5
Hospitalization duration
Daily, till post-operative day 5
Drug side effects (epinephrine + tranexamic acid)
Daily, till post-operative day 5
Complications
Daily, till post-operative day 5
Study Arms (2)
Epinephrine + Tranexamic Acid Group
EXPERIMENTALThe experimental group will receive both epinephrine and tranexamic acid
Tranexamic Acid Group
ACTIVE COMPARATORThe comparator group will receive only tranexamic acid
Interventions
low-dose epinephrine and tranexamic acid
Eligibility Criteria
You may qualify if:
- Patients undergoing knee joint arthroplasty.
- Saudi and Non-Saudi Patient.
- Patients who have Complete medical record.
You may not qualify if:
- End stage renal disease
- Liver cirrhosis
- Coagulopathy
- Pre-operative Hgb \<10 5.
- History of cerebrovascular accident or myocardial infarction in past 12 months.
- History of Heart failure.
- History of arrhythmia.
- History of pheochromocytoma, thyrotoxicosis and glaucoma.
- Pregnancy or breast feeding
- History of Deep venous thrombosis or pulmonary embolism
- Allergy to epinephrine or tranexamic acid
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Abdulaziz Medical City, Ministry of National Guard - Health Affairs
Riyadh, Riyadh Region, Saudi Arabia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wazzan Aljuhani, MD, FRCSC, MBA, MMEd
King Abdulaziz Medical City, MNGHA
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator, Orthopedic Surgeon
Study Record Dates
First Submitted
July 9, 2025
First Posted
July 28, 2025
Study Start
July 15, 2025
Primary Completion (Estimated)
June 24, 2027
Study Completion (Estimated)
June 24, 2027
Last Updated
July 28, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share